GlassScriptPhysician profile
Marc R Baskin
NPI 1124035076
$9,308.89
in general payments reported to CMS, 2019-2025
32 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $856 · 2021: $857 · 2022: $1,932 · 2023: $1,739 · 2024: $1,456 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,315 · Education: $270 · Consulting Fee: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,315.18 |
| Education | $269.97 |
| Consulting Fee | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,443.92 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,986.83 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $584.02 | 2020-2024 | Takhzyro, Cinryze, Cuvitru |
| Genzyme Corporation | $437.47 | 2019-2025 | |
| Abbvie INC. | $396.37 | 2022-2024 | Rinvoq |
| Regeneron Healthcare Solutions, INC. | $340.62 | 2020-2025 | Dupixent |
| Amgen INC. | $319.58 | 2022-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $306.03 | 2023-2025 | Orladeyo |
| Pharming Healthcare, INC. | $298.25 | 2019-2025 | Ruconest |
| Optinose US, INC. | $271.26 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $269.98 | 2022-2024 | |
| Pfizer INC. | $201.98 | 2019-2025 | |
| Csl Behring | $175.47 | 2019-2025 | Haegarda, Andembry |
| Aimmune Therapeutics, INC. | $175.00 | 2022 | |
| Genentech USA, INC. | $140.43 | 2024 | Xolair |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.31 | 2021-2023 | Spiriva Respimat |
| Alk-Abello, INC | $109.68 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Novartis Pharmaceuticals Corporation | $103.63 | 2021-2025 | |
| Incyte Corporation | $89.70 | 2022-2024 | Opzelura |
| Ars Pharmaceuticals Operations, INC. | $79.01 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $75.00 | 2019 | |
| Kaleo, INC. | $74.73 | 2022-2023 | Auvi-Q |
| Phadia US INC. | $59.76 | 2020-2021 | |
| Shire North American Group INC | $41.68 | 2019 | |
| Organon LLC | $40.77 | 2025 | Vtama |
| Cranial Technologies, INC | $35.35 | 2022 | |
| Ionis Pharmaceuticals, INC. | $26.95 | 2025 | Dawnzera |
| Philips North America LLC | $24.40 | 2020 | |
| Cycle Pharmaceuticals INC | $22.65 | 2025 | Sajazir |
| Uswm, LLC | $20.00 | 2021 | |
| Merck Sharp & Dohme LLC | $18.09 | 2019 | |
| Corium, LLC | $17.97 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Baskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.